AB0638 Metabolic syndrome characteristics in patients with primary gout

Background The association between gout and obesity, dyslipidaemia, hypertension and hyperglycaemia is a well-known fact. The presence of most of these abnormalities in the same patient is termed as metabolic syndrome (MetS). MetS increases the risk and the mortality of atherosclerotic cardiovasular diseases (CVDs). In patients with gout the prevalence of MetS is 30% to 82%. Objectives To determine the prevalence of MetS and to examine the association between non-abdominal/abdominal obesity and the components of MetS in patients with primary gout. BMI/ waist circumference (WC) are anthropometric measurements used as indices of total and abdominal obesity. Methods A total of 81 pts with primary (ACR) gout, 95.1% males, underwent physical examination and blood tests. The original National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP) III were used to define MetS. Patients with three or more of the following criteria were defined as having MetS: abdominal obesity (WC≥102cm for men; ≥88cm for women), high TG (≥1,69mmol/L), low HDL(